<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508296</url>
  </required_header>
  <id_info>
    <org_study_id>De-escalation ARDS_2016</org_study_id>
    <nct_id>NCT04508296</nct_id>
  </id_info>
  <brief_title>Goal-directed De-escalation in ARDS</brief_title>
  <official_title>De-escalation Fluid Management Guided by Volumetric Parameters in Patients With Sepsis and ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare two de-escalation strategies guided by either extravascular lung water&#xD;
      or global end-diastolic volume-oriented algorithms in patients with sepsis and ARDS.&#xD;
&#xD;
      Design: A prospective randomized study. Setting: City Hospital #1 of Arkhangelsk, Russia,&#xD;
      mixed ICU. Patients: Sixty patients with sepsis and ARDS were randomized to receive&#xD;
      de-escalation fluid therapy, guided either by extravascular lung water index (EVLWI, n = 30)&#xD;
      or global end-diastolic volume index (GEDVI, n = 30).&#xD;
&#xD;
      Intervention: In case of GEDVI &gt; 650 mL/m2 or EVLWI &gt; 10 mL/kg, diuretics and/or controlled&#xD;
      ultrafiltration were administered. The primary goal of de-escalation was to achieve the&#xD;
      cumulative 48-hr fluid balance in the range of 0 to - 3000 mL. If GEDVI &lt; 650 mL/m2 or EVLWI&#xD;
      &lt; 10 mL/kg, the target fluid balance was set from 0 to +3000 mL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all patients, investigators catheterized the internal jugular or the subclavian vein with&#xD;
      a triple-lumen central venous catheter (Certofix, B|Braun, Germany) and the femoral artery&#xD;
      with a thermistor-tipped arterial catheter (5F, PV2015L20, Pulsion Medical Systems, Munich,&#xD;
      Germany). The arterial blood pressure was recorded from a side port of the catheter.&#xD;
      Hemodynamic monitoring was carried out using the method of transpulmonary thermodilution&#xD;
      (PiCCO2 monitor, Pulsion Medical Systems, Germany) by a triplicate 15 mL bolus of cold (&lt; 8&#xD;
      Â°C) 0.9% saline solution.&#xD;
&#xD;
      Mechanical ventilation (Puritan Bennett 840 and 980, Medtronic, USA) was performed according&#xD;
      to the ARDS Network protocol, using pressure-controlled ventilation with tidal volume 6-7&#xD;
      ml/kg of predicted body weight, with a Ppeak not exceeding 35 cm H2O, positive end-expiratory&#xD;
      pressure (PEEP) and a fraction of inspiratory oxygen (FiO2) levels adjusted to maintain SpO2&#xD;
      within a 92-97% range.&#xD;
&#xD;
      The target fluid balance was achieved by continuous infusion of furosemide with an initial&#xD;
      dose of 0.07 mcg/kg/hr and a minimal duration of 12 hrs. In case of failure to reach a&#xD;
      negative fluid balance by means of diuretics, started controlled ultrafiltration using&#xD;
      continuous veno-venous hemofiltration (CVVH, multiFiltrate, Fresenius Medical Care, Germany).&#xD;
      For fluid replacement, if necessary, investigators administered balanced crystalloid&#xD;
      solutions (Sterofundin Iso/G5, B|Braun, Germany) with an initial infusion rate of 6-7&#xD;
      ml/kg/hr.&#xD;
&#xD;
      Heart rate (HR), MAP, cardiac index (CI), GEDVI, EVLWI, pulmonary vascular permeability index&#xD;
      (PVPI), central venous pressure (CVP), systemic vascular resistance index (SVRI), pulse&#xD;
      pressure variation (PPV), and stroke volume variation (SVV) were assessed using&#xD;
      transpulmonary thermodilution and arterial pulse contour analysis. During the study,&#xD;
      investigators also assessed blood gases (ABL Flex 800 Radiometer, Denmark) and biochemical&#xD;
      parameters (Random Access A-25, BioSystems, Spain). All measurements were performed at&#xD;
      baseline, at 24 and at 48 hrs of the goal-directed de-escalation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of organ function</measure>
    <time_frame>48 hours</time_frame>
    <description>To assess if ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the SOFA scale by more than 20% in comparison with baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence on mortality</measure>
    <time_frame>28-day</time_frame>
    <description>The secondary endpoint was to evaluate whether ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the 28-days mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ARDS, Human</condition>
  <condition>Sepsis, Severe</condition>
  <arm_group>
    <arm_group_label>GEDVI-oriented de-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI &gt; 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI &lt; 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVLWI-oriented de-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI &gt; 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI &lt; 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Goal directed de-escalation therapy</intervention_name>
    <description>Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI &gt; 650 mL/m2 or EVLWI &gt; 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI &lt; 650 mL/m2 or EVLWI &lt; 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL</description>
    <arm_group_label>EVLWI-oriented de-escalation</arm_group_label>
    <arm_group_label>GEDVI-oriented de-escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The presence of sepsis ( the third international definition of sepsis and septic shock&#xD;
             )&#xD;
&#xD;
          -  The precence of ARDS (the Berlin definition of ARDS)&#xD;
&#xD;
          -  mechanical ventilation before the study for at least 24 hrs&#xD;
&#xD;
          -  the age of the patient &gt; 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  continuous infusion of norepinephrine in a dose exceeding 0.4 mcg/kg/min to maintain&#xD;
             mean arterial pressure (MAP) within 65-75 mm Hg,&#xD;
&#xD;
          -  morbid obesity with BMI &gt; 40 kg/m2,&#xD;
&#xD;
          -  severe brain injury,&#xD;
&#xD;
          -  chronic kidney diseases,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  known irreversible underlying conditions such as end-stage neoplasms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Hospital # 1 n.a. E.E. Volosevich</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern State Medical University</investigator_affiliation>
    <investigator_full_name>Mikhail Y. Kirov</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <keyword>de-escalation therapy</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>extravascular lung water</keyword>
  <keyword>global end-diastolic volume</keyword>
  <keyword>sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

